◎ Sugi Atlas

Atlas / Drug / Triphosphate

Triphosphate

drug
On this page

Summary

Triphosphate (CHEMBL1230191) is a phase-3 clinical-stage small molecule targeting P2RY1, P2RY2, and P2RY4; indicated across 1 condition including neoplasm.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 21 (P2RY1, P2RY2, P2RY4…)
  • Indications: 1 condition
  • Chemistry: 257.96 Da · H5O10P3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1230191
NameTriphosphate
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID983
ChEBICHEBI:39949
Molecular formulaH5O10P3
Molecular weight257.96
InChIKeyUNXRWKVEANCORM-UHFFFAOYSA-N

SMILES: OP(=O)(O)OP(=O)(O)OP(=O)(O)O

IUPAC name: diphosphono hydrogen phosphate

Also known as: Triphosphate, TRIPHOSPHATE

Parent form; salt/anhydrous children: CHEMBL3183517

Patent coverage: 35,234 distinct patent families (100,600 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
P2RY1P2Y1 receptorPartial agonist7.80%P47900
P2RY2P2Y2 receptorFull agonist7.11%P41231
P2RY4P2Y4 receptorAgonist5.370%P51582
P2RY11P2Y11 receptorFull agonist5.60%Q96G91
P2RY13P2Y13 receptorFull agonist5.40%Q9BPV8
KCNT2KNa1.20.1%Q6UVM3
KCNJ8Kir6.1Agonist0%Q15842
KCNJ11Kir6.2Antagonist0.1%Q14654
P2RX1P2X1Agonist7.250.3%P51575
P2RX2P2X2Agonist5.852%Q9UBL9
P2RX3P2X3Agonist6.471.6%P56373
P2RX4P2X4Agonist5.91.2%Q99571
P2RX5P2X5Agonist60%Q93086
P2RX6P2X6Agonist60.5%O15547
P2RX7P2X7Agonist3.111.7%Q99572
TRPM4TRPM4Antagonist5.80.5%Q8TD43
ITPR1IP3R11.4%Q14643
RYR1RyR11%P21817
RYR2RyR20.3%Q92736
RYR3RyR30%Q15413
GPR17GPR17Agonist7.431.6%Q13304

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 21 target gene(s): P2RY1, P2RY2, P2RY4, P2RY11, P2RY13, KCNT2, KCNJ8, KCNJ11, P2RX1, P2RX2, P2RX3, P2RX4, P2RX5, P2RX6, P2RX7, TRPM4, ITPR1, RYR1, RYR2, RYR3, GPR17.

Top Reactome pathways

75 total, by targets touching each:

PathwayTargetsGenes
Elevation of cytosolic Ca2+ levels8ITPR1, P2RX1, P2RX2, P2RX3, P2RX4, P2RX5, P2RX6, P2RX7
Platelet homeostasis8ITPR1, P2RX1, P2RX2, P2RX3, P2RX4, P2RX5, P2RX6, P2RX7
P2Y receptors6GPR17, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4
Muscle contraction5ITPR1, KCNJ11, RYR1, RYR2, RYR3
G alpha (q) signalling events5GPR17, ITPR1, P2RY1, P2RY11, P2RY2
Cardiac conduction5ITPR1, KCNJ11, RYR1, RYR2, RYR3
Ion homeostasis5ITPR1, KCNJ11, RYR1, RYR2, RYR3
Transport of small molecules4KCNJ11, RYR1, RYR2, RYR3
G alpha (i) signalling events4GPR17, ITPR1, P2RY13, P2RY4
Stimuli-sensing channels3RYR1, RYR2, RYR3
Ion channel transport3RYR1, RYR2, RYR3
Neuronal System2KCNJ11, KCNJ8
ATP sensitive Potassium channels2KCNJ11, KCNJ8
Inwardly rectifying K+ channels2KCNJ11, KCNJ8
Potassium Channels2KCNJ11, KCNJ8
Metabolism2ITPR1, KCNJ11
Integration of energy metabolism2ITPR1, KCNJ11
Disease2ITPR1, KCNJ11
Regulation of insulin secretion2ITPR1, KCNJ11
Purinergic signaling in leishmaniasis infection2P2RX4, P2RX7
Hemostasis1ITPR1
Opioid Signalling1ITPR1
G-protein mediated events1ITPR1
PLC beta mediated events1ITPR1
Effects of PIP2 hydrolysis1ITPR1
Adaptive Immune System1ITPR1
DAG and IP3 signaling1ITPR1
Signal Transduction1ITPR1
Innate Immune System1ITPR1
Immune System1ITPR1

Dominant GO biological processes

GO termTargets
monoatomic ion transport16
monoatomic ion transmembrane transport15
signal transduction13
calcium ion transmembrane transport13
monoatomic cation transmembrane transport10
cellular response to ATP9
calcium-mediated signaling9
response to ATP9
response to hypoxia7
purinergic nucleotide receptor signaling pathway7
excitatory postsynaptic potential7
G protein-coupled receptor signaling pathway6
calcium ion transport6
phospholipase C-activating G protein-coupled receptor signaling pathway5
G protein-coupled purinergic nucleotide receptor signaling pathway5

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm3MONDO:0005070MONDO:0004992

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

50 molecules share ≥1 primary target. Top 50 by shared-target count:

MoleculeSourceStatusShared targets
SURAMINChEMBLPhase 3P2RX1, P2RX2, P2RX3, P2RX4, P2RX5, P2RX7, P2RY11, P2RY2
ADENOSINE TRIPHOSPHATEChEMBLPhase 2P2RX1, P2RX3, P2RX4, P2RY1, P2RY11, P2RY2, P2RY4
ADENOSINEChEMBL + PubChemPhase 4 (approved)P2RY1, P2RY11, P2RY2, P2RY4
CANGRELORChEMBL + PubChemPhase 4 (approved)P2RX1, P2RY13
glyburideChEMBL + PubChemPhase 4 (approved)KCNJ11, KCNJ8
IndomethacinChEMBL + PubChemPhase 4 (approved)GPR17, P2RY2
DIQUAFOSOLChEMBLPhase 4 (approved)P2RY2, P2RY4
DIQUAFOSOL TETRASODIUMChEMBLPhase 4 (approved)P2RY2, P2RY4
GEFAPIXANTChEMBLPhase 4 (approved)P2RX2, P2RX3
DENUFOSOLChEMBLPhase 3P2RY2, P2RY4
DENUFOSOL TETRASODIUMChEMBLPhase 3P2RY2, P2RY4
PYRIDOXALChEMBLPhase 3P2RX1, P2RX2
URIDINE TRIPHOSPHATEChEMBLPhase 3P2RY2, P2RY4
CROMAKALIMChEMBLPhase 2KCNJ11, KCNJ8
ELIAPIXANTChEMBLPhase 2P2RX2, P2RX3
Berberine ChloridePubChemApprovedKCNJ11, P2RX7
Oxolinic AcidPubChemApprovedRYR2, RYR3
DIAZOXIDEChEMBL + PubChemPhase 4 (approved)KCNJ11
MONTELUKASTChEMBL + PubChemPhase 4 (approved)GPR17
PAROXETINEChEMBL + PubChemPhase 4 (approved)P2RX4
PROPAFENONEChEMBL + PubChemPhase 4 (approved)KCNJ11
TICAGRELORChEMBL + PubChemPhase 4 (approved)P2RY13
BRILLIANT BLUE GChEMBLPhase 4 (approved)P2RX7
CANGRELOR TETRASODIUMChEMBLPhase 4 (approved)GPR17
DULOXETINEChEMBLPhase 4 (approved)P2RX4
PINACIDILChEMBLPhase 4 (approved)KCNJ11
PRANLUKASTChEMBLPhase 4 (approved)GPR17
PROGESTERONEChEMBLPhase 4 (approved)P2RX3
SURAMIN HEXASODIUMChEMBLPhase 3P2RY13
ALADORIANChEMBLPhase 2RYR2
AZD9056ChEMBLPhase 2P2RX7
CE-224535ChEMBLPhase 2P2RX7
CLAMIKALANTChEMBLPhase 2KCNJ11
GAVESTINELChEMBLPhase 2GPR17
JNJ-54175446ChEMBLPhase 2P2RX7
OXATOMIDEChEMBLPhase 2P2RX7
SALFLUVERINEChEMBLPhase 2P2RX1
TIFENAZOXIDEChEMBLPhase 2KCNJ11
ZANVIPIXANTChEMBLPhase 2P2RX7
BelzutifanPubChemApprovedP2RY1
CaffeinePubChemApprovedRYR2
CarbacholPubChemApprovedP2RY2
CarbamazepinePubChemApprovedP2RX4
DantrolenePubChemApprovedRYR2
EslicarbazepinePubChemApprovedP2RX4
OxcarbazepinePubChemApprovedP2RX4
RizatriptanPubChemApprovedGPR17
theophyllinePubChemApprovedP2RX3
tryptophanPubChemApprovedGPR17
ZileutonPubChemApprovedGPR17

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot